ArticleFrontiers in oncology2026
Efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization for unresectable gastrointestinal stromal tumor liver metastases after failure of targeted therapy: a multicenter retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with unresectable gastrointestinal stromal tumor (GIST) liver metastases after the failure of targeted therapy. Methods: 77 patients with unresectable GIST liver metastases who had failed at least two lines of targeted therapy were retrospectively enrolled from three centers between January 2022 to December 2024. Based on their treatment regimen, patients were divided into an observation group (n=34) and a control group (n=43). The control group continued receiving tyrosine kinase inhibitors (TKIs) or best supportive care (BSC). The observation group underwent DEB-TACE followed by TKI therapy or BSC. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS), progression-free survival (PFS), and adverse events during treatment were recorded and analyzed. Results: At the first efficacy evaluation, the observation group exhibited an objective response rate (ORR) of 94.12% (10 complete response [CR], 22 partial response [PR]) and a disease control rate (DCR) of 100%. In the control group, the ORR was 4.65% (2 PR) and the DCR was 39.53%. The median PFS (liver) was significantly longer in the observation group (11.0 months) than in the control group (5.0 months; P < 0.001). The median OS was also longer in the observation group (18.0 months vs. 12.0 months; P < 0.001). Prognostic analysis indicated that better baseline liver function, fewer prior lines of therapy, and DEB-TACE treatment were associated with improved outcomes. Adverse events in the observation group were primarily related to post-embolization syndrome and transient liver injury, with no increase in targeted therapy-related toxicity. Conclusion: DEB-TACE demonstrates favorable efficacy and a manageable safety profile in patients with unresectable GIST liver metastases after targeted therapy failure, representing a safe and feasible treatment option worthy of clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.